GW823093C For The Treatment Of Type 2 Diabetes Mellitus

GW823093 Japan Phase IIa Mono

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00370942

Enrollment

159

Registered

2006-09-01

Start date

2006-04-01

Completion date

2006-11-25

Last updated

2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

GW823093C, diabetes, type 2 diabetes mellitus, DPP-IV inhibitor

Brief summary

This study was designed to find dose response and as extension in treatment of GW823093C.

Interventions

DRUGGW823093C A

A=45 mg

DRUGGW823093C B

B=30 mg

DRUGGW823093C C

C=25 mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 74 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes mellitus. * Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones))

Exclusion criteria

* Patients who have metabolic disease judged by investigator as a clinically significance * Serious cardiovascular disease or serious hepatic disease

Design outcomes

Primary

Measure	Time frame
Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group	12 weeks

Secondary

Measure	Time frame
Long term safety variables	64 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026